Select Publications

  1. Advancing CYP2D6 Pharmacogenetics Through a Pharmacoequity Lens. Clin Pharmacol Ther. 2023 Mar 16.Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A. PMID: 36924260.
  2. Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population. Clin Pharmacol Ther. 2022 11; 112(5):1070-1078.Oni-Orisan A, Haldar T, Cayabyab MAS, Ranatunga DK, Hoffmann TJ, Iribarren C, Krauss RM, Risch N. PMID: 35862449.
  3. Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort. Cardiovasc Diabetol. 2022 07 14; 21(1):132.Haldar T, Oni-Orisan A, Hoffmann TJ, Schaefer C, Iribarren C, Krauss RM, Medina MW, Risch N. PMID: 35836181; PMCID: PMC9284686.
  4. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin. Clin Pharmacol Ther. 2021 09; 110(3):733-740.Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Risch N, Iribarren C, Krauss RM, Oni-Orisan A. PMID: 34114646; PMCID: PMC8376784.
  5. Embracing Genetic Diversity to Improve Black Health. N Engl J Med. 2021 Mar 25; 384(12):1163-1167.Oni-Orisan A, Mavura Y, Banda Y, Thornton TA, Sebro R. PMID: 33567186.
  6. The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change. NPJ Genom Med. 2020; 5:1.Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ. PMID: 31969989; PMCID: PMC6965183.
  7. Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort. Circ Genom Precis Med. 2018 09; 11(9):e002043.Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N. PMID: 30354326; PMCID: PMC6214660.

For a complete list of Oni-Orisan Lab publications, please visit our NCBI bibliography collection.